Dihydroartemisinin for MAFLD

NCT07679542 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

MAFLD

Interventions

DRUG: Dihydroartemisinin

Sponsor

The First Affiliated Hospital with Nanjing Medical University